Products
Online Inquiry
TDZD-8
Cat. No.:
OB0225WX-2141
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
TDZD-8 is a glycogen synthase kinase 3β (GSK-3β) inhibitor with an IC50 of 2 μM, displaying negligible inhibitory activity against PKA, PKC, CDK1, and Casein kinase II.
Synonym:
GSK-3β Inhibitor I; NP 01139; 327036-89-5; 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione; GSK-3beta Inhibitor I; MFCD04973552; 1,2,4-Thiadiazolidine-3,5-dione, 2-methyl-4-(phenylmethyl)-; 2-methyl-4-(phenylmethyl)-1,2,4-thiadiazolidine-3,5-dione; GSK-3beta Inhibitor I;NP 01139; TDZD 8; Thiadiazolidinone-8; TDZD8; GSK-3 beta Inhibitor I; 4-Benzyl-2-methyl-[1,2,4]thiadiazolidine-3,5-dione
CAS No.:
327036-89-5
Compound CID:
4124851
Formula:
C10H10N2O2S
Formula Weight:
222.26
Specification
Targets&IC50:
GSK-3β: 2 μM
Relative Density:
1.375 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
TDZD-8 is utilized in neuropharmacology and inflammation research as a non-ATP competitive GSK-3 beta inhibitor to investigate its neuroprotective effects and its ability to reduce pro-inflammatory cytokine production.
Library Information
Target:
GSK-3
Receptor:
GSK-3β
Pathways:
Stem cells; PI3K/Akt/mTOR signaling
Plate Number:
AOCL-28
Plate Location:
d6
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
70 mg/mL; 314.95 mM
Water Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Ethanol Max Solubility:
44.5 mg/mL; 200.21 mM
